1293.TWO Lytone Enterprise, Inc.
- Market cap
- TWD 374M
- P/E
- 12.4x
- P/B
- 1.58x
- ROE
- 14.4%
- Dividend yield
- 5.94%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 1293.TWO undervalued?
Graham number1293.TWO trades 6.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lytone Enterprise, Inc. fundamental analysis
No fundamental analysis for Lytone Enterprise, Inc. yet.
Lytone Enterprise, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lytone Enterprise, Inc.
Lytone Enterprise, Inc. engages in the research, design, and development of functional food products, and animal husbandry and agricultural biotechnology products in Taiwan. It offers post-harvest techniques; functional fertilizers; and livestock feed additives comprising immune stimulators, growth promoters, and health improvement products. The company also provides food ingredients, such as plant extracts, animal tissue extracts, and probiotics; and healthy foods, includin…
Full company profileLytone Enterprise, Inc. financial statements
Lytone Enterprise, Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 318M | 286M | 330M | 287M | 426M | 467M | 532M | 599M | 679M | 763M |
| Gross Profit | 122M | 118M | 144M | 129M | 188M | 194M | 202M | 227M | 248M | 266M |
| Operating Income | 6.42M | 3.66M | 12.6M | -6.26M | 45.5M | 43.2M | 40.5M | 42.1M | 37.8M | 47.5M |
| EBITDA | 8.25M | 12.1M | 19.1M | 10.1M | 61.7M | 60.9M | 58.6M | 58.8M | 65.3M | 66.9M |
| Net Income | 1.31M | 1.98M | 4.00M | -5.59M | 43.3M | 36.6M | 32.1M | 28.7M | 36.9M | 37.8M |
| EPS | 0.14 | 0.21 | 0.43 | -0.59 | 4.69 | 2.28 | 1.87 | 1.67 | 2.15 | 2.21 |
| Balance Sheet | ||||||||||
| Total Assets | - | - | - | - | 261M | 303M | 362M | 444M | 472M | 516M |
| Total Liabilities | - | - | - | - | 135M | 123M | 153M | 219M | 224M | 253M |
| Shareholders' Equity | - | - | - | - | 126M | 180M | 209M | 225M | 248M | 263M |
| Cash & Short-term Investments | - | - | - | 11.6M | 64.3M | 85.4M | 88.7M | 179M | 169M | 163M |
| Total Debt | - | - | - | - | 59.8M | 36.6M | 42.5M | 89.3M | 82.9M | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | - | - | - | 11.5M | 31.4M | 38.3M | 15.1M | 78.5M | 33.6M | 16.0M |
| Capital Expenditure | - | - | - | 5.32M | 4.02M | 5.00M | 2.43M | 5.75M | 10.8M | 8.85M |
| Free Cash Flow | - | - | - | 6.16M | 31.2M | 29.7M | 13.7M | 72.7M | 22.9M | 7.18M |
| Ratios | ||||||||||
| ROE | - | - | - | - | 34.5% | 20.3% | 15.3% | 12.7% | 14.9% | 14.4% |
| ROA | - | - | - | - | 16.6% | 12.1% | 8.9% | 6.5% | 7.8% | 7.3% |
| Net Profit Margin | 0.4% | 0.7% | 1.2% | -2.0% | 10.2% | 7.8% | 6.0% | 4.8% | 5.4% | 5.0% |
| Debt to Equity | - | - | - | - | 0.48x | 0.20x | 0.20x | 0.40x | 0.33x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lytone Enterprise, Inc. dividends
- Dividend yield
- 5.94%
- Forward dividend
- 1.50 TWD
- Payout ratio
- 58.7%
- Ex-dividend date
- Apr 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 22.2M | 1.30 | 58.7% |
| 2024 | TWD 17.1M | 1.00 | 46.3% |
| 2023 | TWD 11.4M | 0.66 | 39.8% |
| 2022 | TWD 3.57M | 0.21 | 11.1% |
| 2021 | TWD 12.0M | 0.75 | 32.9% |
| 2020 | 643K | 0.07 | 1.5% |
| 2019 | 2.14M | 0.23 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1050:1000 on Aug 7, 2023.
Who owns Lytone Enterprise, Inc.
Ownership data of Lytone Enterprise, Inc. is not available yet.
Lytone Enterprise, Inc. company profile
- Company name
- Lytone Enterprise, Inc.
- Ticker
- 1293.TWO
- ISIN
- TW0001293009
- Exchange
- Taiwan OTC Exchange
- Sector
- Consumer Defensive
- Industry
- Farm Products
- Fiscal year end
- December
- Address
- No. 31-1, Lane 169, Kangning St., New Taipei City, Taiwan, 22180
- Phone
- 886 2 2694 0885
- Website
- lytone.com
About Lytone Enterprise, Inc.
Lytone Enterprise, Inc. engages in the research, design, and development of functional food products, and animal husbandry and agricultural biotechnology products in Taiwan. It offers post-harvest techniques; functional fertilizers; and livestock feed additives comprising immune stimulators, growth promoters, and health improvement products. The company also provides food ingredients, such as plant extracts, animal tissue extracts, and probiotics; and healthy foods, including metabolic syndrome improvements, skin and hair care, neuroprotection, gastrointestinal care, and allergy improvement products. It operates in China, Europe, the United States, Japan, Korea, Southeast Asia, New Zealand, Australia, and East Africa. Lytone Enterprise, Inc. was founded in 1994 and is headquartered in New Taipei City, Taiwan.
Lytone Enterprise, Inc. management
7- Dr. T. H. Chang Ph.D.Executive Chairman
- Ms. Yan LinGeneral Manager
- Mr. Pei Xie CaiChief Financial Officer
- Ms. Tian Kun ZhangAssistant Manager of Administration Department
- Ms. Juan-Juan SuSenior Vice President of New Business Development Department
- Chen Ming ZhangChief Sustainability Officer
- Mr. Ying Jue ZhangDeputy GM of the Management Department & Chief Information Security Officer